Trial Profile
A Phase 3, Randomised, Parallel-group, Active-controlled, Double-blind Study to Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 19 Apr 2022
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Celltrion
- 16 Mar 2021 Status changed from active, no longer recruiting to completed.
- 08 Dec 2020 Results presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.
- 21 Jun 2020 Results of pooled analysis of two phase three trials, assessing Safety Profile of Rituximab Biosimilar Ct-P10 in Follicular Lymphoma patients presented at the 25th Congress of the European Haematology Association